MedTrace Logo

Vitiligo, New Treatment and Serum s100B

NCT06768840 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-01-10

No results posted yet for this study

Summary

vitiligo is an autoimmune depigmenting skin disorder characterized by milky white macules or patches, with 2% worldwide prevalence. Vitiligo has unexpected course that significantly influences on patient's quality of life and self-esteem.

Multiple medications have been introduced for vitiligo treatment, in this study we work on one of systemic JAK inhibitors

Conditions

  • Vitiligo, Generalized

Interventions

DRUG

Baricitinib

oral baricitinib 4mg for adults and 2mg for children 10-16 years for group A

DRUG

oral mini pulse

pulse dose of oral dexamethasone 2.5mg for adults for two consecutive days per week and half the dose for children

RADIATION

Narrow Band UVB Treatment

narrowband ultraviolet rays B phototherapy two sessions per week

Sponsors & Collaborators

  • South Valley University

    lead OTHER

Principal Investigators

  • EMAN A OSMAN, bachelor · Qena university hospital, Qena faculty of medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
10 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-02
Primary Completion
2025-08-31
Completion
2025-10-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06768840 on ClinicalTrials.gov